How many drugs treat Medullary thyroid carcinoma?

Drug Landscape tracks 7 marketed treatments for Medullary thyroid carcinoma (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/medullary-thyroid-carcinoma.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Medullary thyroid carcinoma — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Medullary thyroid carcinoma (disease) competitive landscape: 7 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

7 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Medullary thyroid carcinoma, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Retevmo	SELPERCATINIB	Eli Lilly	Kinase Inhibitor [EPC]	Proto-oncogene tyrosine-protein kinase receptor Ret	2020-01-01
Gavreto	PRALSETINIB	Rigel Pharms	Kinase Inhibitor [EPC]	RET	2020-01-01
Cometriq	Cabometyx	Exelixis	Kinase Inhibitor	Vascular endothelial growth factor receptor 2	2012-01-01
Cometriq	CABOZANTINIB	Exelixis Inc	Kinase Inhibitor	Vascular endothelial growth factor receptor 2	2012-01-01
Caprelsa	VANDETANIB	Sanofi	Kinase Inhibitor [EPC]	Receptor-interacting serine/threonine-protein kinase 2	2011-01-01
Caprelsa	Caprelsa	Genzyme, a Sanofi Company		AarF domain-containing protein kinase 4, Bone morphogenetic protein receptor type-1B, Chaperone activity of bc1 complex-like, mitochondrial
Zactima	Zactima	Barbara Ann Karmanos Cancer Institute		AarF domain-containing protein kinase 4, Bone morphogenetic protein receptor type-1B, Chaperone activity of bc1 complex-like, mitochondrial

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Barbara Ann Karmanos Cancer Institute · 1 drug in Medullary thyroid carcinoma
Eli Lilly · 1 drug in Medullary thyroid carcinoma
Exelixis · 1 drug in Medullary thyroid carcinoma
Exelixis Inc · 1 drug in Medullary thyroid carcinoma
Genzyme, a Sanofi Company · 1 drug in Medullary thyroid carcinoma
Rigel Pharms · 1 drug in Medullary thyroid carcinoma
Sanofi · 1 drug in Medullary thyroid carcinoma

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Medullary thyroid carcinoma:

Cite this brief

Drug Landscape (2026). Medullary thyroid carcinoma — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/medullary-thyroid-carcinoma. Accessed 2026-06-10.

Medullary thyroid carcinoma full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing